Weekly Variability of an Objective Bradykinesia Score in Parkinson’s Disease—An Observational Longitudinal Study
Journal of Clinical Medicine · 06.05.2026 · 15 (9) · 3545
DOI: 10.3390/jcm15093545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.05.2026. Verfasst von Marcus Dalsgaard Hansen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorder Clinic, Rigshospitalet, 2600 Copenhagen, Denmark. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jascha Foundation, Novo Nordisk Foundation, Capitol Region Research Foundation.
Abstract (Originalsprache)
Background
Parkinson’s Disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. Effective management is critical to improving patient outcomes but is limited by the subjectivity of retrospective assessments of motor symptom burden. The objectives were to describe the weekly variability of objective bradykinesia score (BKS) derived from a wrist-worn device and assess the correlation between BKS variability and the Quality of Life (QoL) of People with Parkinson’s disease (PwP).
Method
This observational, longitudinal study is part of the overall self-management project, Empower-PD. The study population consists of 80 PwP. Participants wore a wrist-worn accelerometer watch that measures movement during daily activities to evaluate the degree of bradykinesia as the bradykinesia score (BKS). Weekly median BKSs were collected over a 10-week period. Quality of life was assessed with the PDQ-39 questionnaire at baseline and after 10 weeks. Descriptive statistics assessed BKS variation and distribution. Linear and logistic regression models examined correlations between variability in BKS and QoL.
Results
Results showed that 95% of BKS weekly changes were in a range between −4.3 and +4.4 points, with a central tendency near zero. The distribution of BKSs over time indicated that most participants exhibited stable BKSs. No significant correlation was found between BKS changes and QoL at 10 weeks.
Conclusions
This study successfully described weekly BKS variations over ten weeks in PwP using objective measurements. The results showed that 95% of all value changes in BKS ranged from −4.3 to 4.4, values which may serve as preliminary distribution-based reference bounds that could inform the design of future studies examining clinically significant changes in BKS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Movement Disorder Clinic, Rigshospitalet, 2600 Copenhagen, Denmark.
- Health Informatics, Department of Public Health, University of Copenhagen, 2200 Copenhagen, Denmark.
- Department of Clinical Neuroscience, University of Gothenburg, 413 45 Gothenburg, Sweden.
- Department of Neurology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
- Department of Brain-and Spinal Cord Injuries, Rigshospitalet, 2600 Copenhagen, Denmark.
- Department of Health Technology, Technical University of Denmark, 2800 Lyngby, Denmark.
ORCID-Profile: Marcus Dalsgaard Hansen, Filip Bergquist
Förderung
- Jascha Foundation
- Novo Nordisk Foundation
- Capitol Region Research Foundation
Zitieren
APA
Hansen, M. D., Bergquist, F., & Thomsen, T. H. (2026). Weekly Variability of an Objective Bradykinesia Score in Parkinson’s Disease—An Observational Longitudinal Study. Journal of Clinical Medicine, 15(9), 3545. https://doi.org/10.3390/jcm15093545
Vancouver
Hansen MD, Bergquist F, Thomsen TH. Weekly Variability of an Objective Bradykinesia Score in Parkinson’s Disease—An Observational Longitudinal Study. Journal of Clinical Medicine. 2026;15(9):3545. doi:10.3390/jcm15093545
BibTeX
@article{Hansen2026,
author = {Hansen, Marcus Dalsgaard and Bergquist, Filip and Thomsen, Trine Hørmann},
title = {Weekly Variability of an Objective Bradykinesia Score in Parkinson’s Disease—An Observational Longitudinal Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {9},
pages = {3545},
doi = {10.3390/jcm15093545}
}
EUVIMED